Sangamo Therapeutics’ (SGMO) Buy Rating Reaffirmed at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 358.72% from the company’s current price.

SGMO has been the subject of several other reports. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating for the company. Barclays upped their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday.

Sangamo Therapeutics Trading Down 10.7 %

Shares of SGMO stock traded down $0.26 during mid-day trading on Thursday, reaching $2.18. The stock had a trading volume of 5,717,917 shares, compared to its average volume of 6,921,396. The business has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $0.84. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company has a market cap of $453.92 million, a P/E ratio of -2.88 and a beta of 1.10.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Sangamo Therapeutics by 16.5% in the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 77,032 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 57,125 shares during the period. Meritage Portfolio Management raised its position in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the last quarter. Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 35.2% in the 3rd quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 69,368 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares during the period. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.